We use cookies for behaviour analytics. Learn more
Healthcare · Equity Analysis
Pfizer Inc. (PFE) Stock Analysis - DCF Valuation & AI Disruption Risk
By Anton Ladnyi, CFA · ex-Goldman Sachs · ex-J.P. MorganPublished Updated
PFE — CFO Dave Denton departure announced June 18 (effective August 15); Cecile Guegan named interim CFO. Sigvotatug vedotin Phase 3 FAILED primary OS endpoint in broad NSCLC population — Seagen ADC strategy faces execution questions. Stock ~$23.67 (below $29 base case). FY2026 guide $59.5-62.5B / $2.80-3.00 EPS unchanged.
Composite rating with analyst overlay — not individualized investment advice.
How Is This Rating Calculated?
A.L. Capital Advisory Equity Composite model · calculated 2026-08-08. Four calculation steps, in order — steps 1, 2 and 4 are rules-based; step 3 is a disclosed qualitative analyst overlay mapped to a fixed numerical scale:
1. Margin of safety → quantitative grade
PFE's margin of safety is +36.82% (base case $42 vs. price $26.76). Margin of safety here is defined as (fair value − price) / fair value — this is the formula the quant grade below is actually assigned from. It is not the same figure as the gauge's "Upside to Base" pill above, which uses (fair value − price) / price and will read a larger number for the same inputs. For comparison, the pure (unblended) DCF output alone implies a margin of safety of +67.96% (pure DCF base $84 vs. price $26.76) — the gap between this and the +36.82% blended figure above reflects the analyst-consensus blend.
Rules are cumulative (multiple can fire on the same ticker) and purely mechanical — no analyst judgment is involved in step 2.
3. Thesis conviction modifier
Analyst conviction: low · modifier: -0.60. This is a qualitative analyst judgment on the written thesis, mapped to a fixed numeric modifier below — it is not algorithmically derived from a measurable indicator.
Analyst-conviction modifier scale
Conviction level
Modifier
Very High
+1.00
High
+0.60
Medium
+0.00
Low
-0.60
Very Low
-1.00
General guidance for the assigning analyst (not an algorithmic rule — conviction is assigned by editorial judgment on the written thesis, not computed): Very High/High — multiple thesis pillars confirmed by the most recent reported quarter, no unresolved red flags. Medium — mixed evidence, or a thesis not yet differentiated enough to lean either direction. Low/Very Low — one or more thesis pillars deteriorating, or a material data-quality concern. Assigned and reviewed each time the underlying thesis is updated (see the thesis "last updated" date on this page).
Rating sensitivity: without the -0.60 analyst-conviction overlay, PFE would score 4.50 and carry a Strong Buy rating instead of Buy. The overlay is the deciding factor between these two ratings.
This is the exact formula the model runs — not a post-hoc explanation. Source: composite_grade.py, A.L. Capital Advisory Equity Composite.
PFE Price Target & Rating
PFE's composite rating is Buy (quantitative grade: Strong Buy), with limited downside risk (CVaR -8.7%), and quality metrics (net margin 7%, ROE 5%). Pfizer Inc. (PFE) trades at $26.76 with a Buy composite rating and a quantitative grade of Strong Buy: a trailing P/E of 34.3x at a 56% premium to sector median, net margins of 6.8%, a blended fair-value range of $33–$56 suggesting a +37% margin of safety, beta 0.28 (defensive risk profile).
What Is PFE's DCF Intrinsic Value and Blended Fair Value Range?
PFE's blended fair-value range is $33–$56 (base case $42), against a current price of $26.76.
PFE blended fair-value gauge — bear case $33, base case $42, bull case $56, current price $26.76.
Price & DCF data as of
How Does PFE's Margin of Safety Change as the Price Moves?
Drag to simulate PFE's price moving between the blended bear ($33) and bull ($56) fair-value anchors — left for a price fall, right for a rise — and see how the margin of safety vs A.L. Capital Advisory's $42 blended base-case fair value changes. Starting point: the page's as-of price of $26.76 on 2026-08-08.
DCF Assumptions
Two-stage earnings-based DCF on forward EPS of $2.89 (Yahoo Finance forwardEps: provider-aggregated next-fiscal-year consensus estimate, not a fixed trailing-12-month window): explicit 5-year forecast at the stage-1 growth rate below, discounted at the CAPM cost of equity, plus a Gordon Growth terminal value at the terminal growth rate, also discounted at the CAPM cost of equity. This model discounts projected EPS — an equity-level metric — directly, not free cash flow, so the cost of equity is the theoretically correct discount rate; this is not a debt-weighted WACC (no cost of debt or capital-structure weighting is applied). Source: A.L. Capital Advisory DCF engine (api.py).
DCF assumptions by scenario
Input
Bear
Base
Bull
Stage-1 (near-term) growth
4.50%
10.00%
15.00%
Terminal growth
2.50%
2.50%
2.50%
CAPM cost of equity (discount rate)
8.00%
7.41%
6.82%
Forecast horizon
5 years
5 years
5 years
CAPM cost of equity = risk-free rate (4.66%, a live 10-year Treasury yield (Yahoo Finance ^TNX) fetched at page-generation time, 2026-08-08T10:24:15+00:00 UTC) + beta (0.50) × 5.5% equity risk premium, floored at 6% and capped at 18%. Stage-1 growth is a sector-level base rate (bear/bull apply 0.45x/1.50x multipliers); terminal growth is held constant across scenarios. Bear/bull cost of equity applies a ±8% relative adjustment to the base rate, clamped to the same 6–18% band.
The DCF output above is not the final intrinsic value shown elsewhere on this page. It is blended with the Wall Street analyst consensus price target to avoid extreme single-model divergence, weighted by analyst coverage depth (26 analysts covering this stock → 25.00% DCF / 75.00% consensus). The blended figure is the intrinsic value used for margin-of-safety and the composite rating.
DCF-to-intrinsic-value blend by scenario
Scenario
Pure DCF value
Analyst target used
Blended intrinsic value (displayed)
Bear
$58.78
$25.00
$33.45
Base
$83.53
$28.63
$42.36
Bull
$117.43
$35.46
$55.95
Blended value = (25.00% × pure DCF) + (75.00% × analyst target). Bear/bull scenarios blend against the analyst low/high target rather than the mean.
Analyst-coverage-to-consensus-weight tiers
Analyst coverage
Weight
0–1 analysts
0.00% consensus / 100.00% DCF
2–4 analysts
40.00% consensus / 60.00% DCF
5–19 analysts
65.00% consensus / 35.00% DCF
20+ analysts
75.00% consensus / 25.00% DCF
The consensus weight is a fixed step function of analyst coverage depth (above), not adjusted for target age, dispersion, or outliers — the mean/low/high analyst targets are used as reported by the data provider with no filtering.
Risk: CVaR -8.7% (95th percentile, 1-month) indicates moderate tail exposure; beta of 0.28 amplifies broad market moves in both directions
Strengths: Size 4.0/5, 7% net margin, 5% ROE dominate the factor profile
Catalyst: New permanent CFO appointment (timeline unknown); Sigvotatug vedotin subgroup analysis and revised indication strategy; PADCEV Phase 3 EV-304 final data (key Seagen validation); FY2026 guidance reaffirm vs $59.5-62.5B at Q2 earnings; Eliquis biosimilar entry timing (affects base revenue)
Bear catalyst: Dividend cut; second ADC safety signal; management reduces 2029+ guidance to mid-single-digit CAGR; net debt rises above $40B
PFE — Quantitative SnapshotAugust 2026
RatingBuy
Price$26.76
Why BuyDCF model implies +37% margin of safety — valuation gap offsets weak near-term quality signals
Main riskPremium multiple (34.3x P/E) demands consistent delivery
Tail riskCVaR -8.7% over one month at the 95th percentile
Blended fair-value range$33–$56 blended fair-value range; margin of safety +37%
Best useCore large-cap Healthcare holding — not a source of diversified sector exposure
Next watchEarnings delivery consistency and margin trajectory
How Does PFE Score on the Five-Factor Quantitative Model?
PFE's composite five-factor score is 3.0/5, led by Volatility (5.0/5) and weakest on Quality (1.0/5).
PFE five-factor radar — Value 2.0, Quality 1.0, Momentum 3.0, Volatility 5.0, Size 4.0 (out of 5).
Value
2.0 / 5
Quality
1.0 / 5
Momentum
3.0 / 5
Volatility
5.0 / 5
Size
4.0 / 5
PFE Five-Factor Quantitative Scores
Factor
Score
Value
2.0 / 5
Quality
1.0 / 5
Momentum
3.0 / 5
Volatility
5.0 / 5
Size
4.0 / 5
What Is PFE's AI-Era Durability and Disruption Risk?
AI Disruption Risk: Elevated
Pfizer sits near the center of what analysts are calling a patent cliff of 'tectonic magnitude': the co-developed Eliquis franchise is exposed to Medicare's IRA drug-price negotiation program, with the first 10 negotiated prices taking effect January 1, 2026 and a second round of 15 drugs following in 2027, while the industry broadly faces $180-400B in cumulative brand-sales erosion from patent and biosimilar exposure through 2030-2033. AI is not a material differentiator in Pfizer's disclosed strategy; the company's actual response has been M&A-led, deploying $10B+ deals to acquire external pipeline assets to fill the post-cliff revenue gap, a pattern shared with Merck. The IRA's 9-year small-molecule negotiation window has also been cited industry-wide as a factor pushing R&D funding away from small molecules toward biologics, a structural shift affecting Pfizer's future pipeline mix. Watch the outcome of Pfizer's legal challenges to IRA negotiation and the pace of bolt-on M&A as signals for whether the cliff is being managed or merely delayed.
Key Metrics
PFE Key Metrics — Pfizer Inc. 2026
Metric
Value
Current Price
$26.76
P/E Ratio (TTM)
34.3x
Forward P/E
9.3x
P/S Ratio
2.4
EV/EBITDA
8.1
Beta
0.28
Net Margin
6.8%
ROE
5.0%
Debt/Equity
74.3%
Dividend Yield
6.56%
CVaR (95%, 1M)
-8.7%
Market Cap
$152.5B
1-Month CVaR Methodology
The 1M CVaR-95 figure shown in Key Metrics, the peer comparison table and this page's hero card is computed as follows:
Lookback: most recent 1 year of daily prices.
Return input: daily log returns on dividend/split-adjusted close prices.
Confidence level: 95% (worst 5% of the resulting rolling-month observations).
Quantile convention: floor-based cutoff — the worst floor(N × 0.05) rolling-month observations (minimum 1), not a rounded or interpolated percentile.
CVaR: arithmetic mean of that worst-5% tail, expressed as a percentage.
Corporate actions: reflected via adjusted-close pricing (dividends and splits are accounted for).
1M CVaR-95 by lookback window
Method
1M CVaR-95
Trailing 1-year historical
-8.7%
Trailing 3-year historical
-13.1%
Trailing 5-year historical
-13.7%
The 1-year figure is what appears elsewhere on this page. Because it is built from overlapping 21-day windows over a single year, it reflects roughly the last ~11 non-independent tail events and is sensitive to the specific market regime of that year — treat it as a trailing-window historical estimate, not a structurally stable long-run risk parameter. The 3- and 5-year figures use the same methodology over longer, more regime-diverse histories.
This is a separate calculation from the 1-Day VaR/CVaR shown in the Tail Risk Profile chart below, which uses raw (non-overlapping) daily returns rather than rolling monthly sums — see that chart's own methodology note for the daily-horizon convention.
Tail Risk Profile
Historical Simulation · Daily Log Returns
PFE — Daily Return Distribution
Pfizer Inc. · 250 trading days · CVaR illustrated on real data
Aug 2025 – Aug 2026
Daily log returns
95%
-2.27%
1-Day VaR · 95%
95th-percentile loss threshold
-2.94%
1-Day CVaR · 95%
Avg loss in tail
13
Days in tail
of 250 sessions
250
Daily returns
Aug 2025 – Aug 2026
Historical VaR uses the nearest-rank convention: the worst observation within the tail (empirical (1−confidence) fraction of trading days). Historical CVaR is the arithmetic mean of all observations at or below that VaR threshold — so VaR is always included inside the CVaR tail, not one observation outside it.
Anton Ladnyi, CFA · A.L. Capital AdvisoryUpdated 2026-08-08
Rating Rationale
PFE — CFO Dave Denton departure announced June 18 (effective August 15); Cecile Guegan named interim CFO. Sigvotatug vedotin Phase 3 FAILED primary OS endpoint in broad NSCLC population — Seagen ADC strategy faces execution questions. Stock ~$23.67 (below $29 base case). FY2026 guide $59.5-62.5B / $2.80-3.00 EPS unchanged.
Investment Thesis
↑ Bull Case
Seagen ADC platform: PADCEV FDA-approved (EV-303, ASCO 2026) as perioperative neoadjuvant+adjuvant in muscle-invasive bladder cancer — first MIBC perioperative approval; sigvotatug vedotin (IB6-ADC) Phase 1 data supports Phase 3 SigVie-003 in NSCLC; ~20 pivotal oncology studies starting 2026
Talzenna + Xtandi: positive Phase 3 TALAPRO-3 in metastatic prostate cancer (March 2026) — new approved combination indication expanding urological oncology
At 8-9x forward P/E and 6.8% yield, most of the patent cliff appears priced in; any pipeline success delivers asymmetric upside
Management target: high single-digit revenue CAGR from 2029 onward — if ADC platform delivers, 3-year holding returns could be substantial
Metsera acquisition brings ultra-long-acting GLP-1 assets; 10 pivotal trials planned 2026 with first approval targeted 2028
Seagen integration driving oncology-focused portfolio transformation with next-gen ADC pipeline including PADCEV Phase 3 EV-304 (urothelial cancer) and sigvotatug subgroup analysis — multiple pipeline catalysts through 2027 can offset CFO transition uncertainty and provide re-rating events from current deeply discounted 8-9x P/E
Danuglipron discontinued (liver injury signal): eliminates Pfizer as a 2026-2027 GLP-1 competitor; Metsera is a 2028+ story at best
COVID revenue: $56.7B peak in 2022 → ~$5B in 2026 — secular collapse not cyclical; never returns
Guidance not raised despite Q1 beat — management reserving for tariff and pricing uncertainty; signals lack of visibility
Dividend sustainability: 6.8% yield at ~100% GAAP payout ratio requires ADC cash flows to materialise; any cut would be brutal
Sigvotatug vedotin Phase 3 FAILED primary OS endpoint in broad NSCLC population (June 2026) — raises fundamental questions about the Seagen ADC acquisition thesis at $43B acquisition cost; subgroup analyses cannot rescue a broad-population failure as primary commercial indication
CFO Dave Denton departure (August 15, June 18 announcement) mid-year creates leadership uncertainty; interim CFO Guegan inherits ongoing $4B+ cost restructuring and potential guidance pressure — consecutive C-suite transitions (post-Bourla era) signal instability
What Changes the Rating
↑Catalyst:Seagen ADC produces two additional approvals in 2026-2027; management raises FY2026 guidance above $62.5B; dividend maintained with clear FCF coverage
↓Model downgrade conditions:Dividend cut; second ADC safety signal; management reduces 2029+ guidance to mid-single-digit CAGR; net debt rises above $40B
Anton’s personal note
PFE earns a Buy from the model, and I agree on direction. But premium multiples concentrate the risk in execution — there is not much room for a soft quarter at 34x. What I pay attention to above all else is the earnings surprise trajectory. The beat streak is intact, but the magnitude has compressed from +37.4% to +12.9% — and at a 34x multiple, the market is not pricing in a miss. That asymmetry is worth respecting. The setup that would make me more positive is a quarter that confirms the operating leverage story. The setup that would make me cautious is any signal that consensus estimates are getting ahead of fundamentals.
— Anton Ladnyi, CFA
Earnings History
PFE Earnings History — EPS Surprise Rate 2026
Quarter
EPS Est. (consensus)
EPS Actual (adjusted, consensus basis)
Surprise
Q2 2026
$0.68
$0.77
+12.9% ✓
Q1 2026
$0.72
$0.75
+3.9% ✓
Q4 2025
$0.57
$0.66
+16.2% ✓
Q3 2025
$0.63
$0.87
+37.4% ✓
EPS Actual is on the same adjusted/non-GAAP basis as the consensus estimate it is compared against (excludes one-time items, consistent with how Wall Street EPS estimates are typically constructed) — it will generally differ from the company's GAAP diluted EPS as reported in its official financial statements. Verify the GAAP figure against the issuer's original earnings release if that basis is what you need.
How Has PFE Performed vs. Wall Street EPS Estimates?
PFE has beaten consensus EPS estimates in 4 of the last 4 reported quarters (100%).
PFE quarterly EPS — estimate vs. actual, 4 most recent reported quarters, 100% beat rate.
Earnings Projections
PFE Forward EPS Consensus Estimates 2026
Quarter
EPS Est.
YoY EPS
Analysts
Q3 2026
$0.78
-10.3%
18
Q4 2026
$0.71
+8.2%
18
Q1 2027
~$0.71
-5.3%
24
Q2 2027
~$0.72
-6.5%
23
~ Estimated from annual consensus — not a direct analyst survey
What Are Wall Street's EPS Estimates for PFE?
Wall Street's next-quarter consensus EPS estimate for PFE is $0.78.
PFE consensus EPS estimates, next quarter $0.78, 4 quarters shown.
Revenue growth × exit multiple (editorial, not mechanically reproducible from disclosed inputs) · hover each scenario for detail · current price $26.76
▼
Bear Case
$18
-32.7%
Implied NTM P/E: 6.2x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
-5.0 revenue CAGR · 7.0 exit multiple
◆
Base Case
$29
+8.4%
Implied NTM P/E: 9.9x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
3.0 revenue CAGR · 10.0 exit multiple
▲
Bull Case
$42
+57.0%
Implied NTM P/E: 14.4x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
10.0 revenue CAGR · 14.0 exit multiple
How Correlated Is PFE With Its Sector Peers?
0 of 10 peer pairs correlated above 0.60, indicating meaningful historical diversification across the selected names, although all remain exposed to common equity, sector and macro factors.
PFE pairwise correlation heatmap across 5 peers — 0 of 10 pairs above 0.60.
0 of 10 peer pairs correlated above 0.60, indicating meaningful historical diversification across the selected names, although all remain exposed to common equity, sector and macro factors.
Extended Analysis — Buy, Hold or Sell? Risk Factors. Portfolio Fit.
Is PFE a buy, hold, or sell?
PFE carries a quantitative grade of Strong Buy. The trailing P/E of 34.3 sits 56% above the Healthcare sector median of 22.0x — a premium that demands sustained earnings delivery. Our two-stage, EPS-based DCF model produces a pure model range of $59–$117. After blending with Street consensus targets, the displayed fair-value range is $33–$56 — implying a +37% margin of safety vs. blended base fair value at the current price of $26.76. The width of the range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
PFE has beaten consensus estimates in 100% of the last 4 reported quarters, signalling strong execution consistency. The most recent quarter delivered a 12.9% earnings surprise. Analyst estimate revisions are trending upward.
What are PFE's key risk factors?
With a beta of 0.28, PFE exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -8.7% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this standalone tail outcome corresponds to approximately 0.9% of portfolio value before accounting for correlations with other holdings — not a marginal portfolio CVaR contribution, which depends on the full covariance structure. Net margins of 6.8% fall below the Healthcare sector average of 18%, suggesting margin pressure. The balance sheet is conservatively leveraged at 74% debt-to-equity.
At 0.55, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 24.8% exceeds realized volatility of 17.6% by 7 points, suggesting options are pricing in elevated risk. Insider transactions show net buying of $72.8M over the disclosed transactions from 2024-08-13 to 2026-08-05, a signal often associated with management confidence. Short interest is low at 2.9% of float, suggesting limited bearish conviction.
How does PFE fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — PFE carries a beta of 0.28, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, PFE shows the strongest co-movement with BMY (0.58), MRK (0.52), AZN (0.48). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The PFE analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning PFE’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
Investor FAQ
What is PFE's AI-Era Durability & Disruption Risk Score?
Pfizer sits near the center of what analysts are calling a patent cliff of 'tectonic magnitude': the co-developed Eliquis franchise is exposed to Medicare's IRA drug-price negotiation program, with the first 10 negotiated prices taking effect January 1, 2026 and a second round of 15 drugs following in 2027, while the industry broadly faces $180-400B in cumulative brand-sales erosion from patent and biosimilar exposure through 2030-2033. AI is not a material differentiator in Pfizer's disclosed strategy; the company's actual response has been M&A-led, deploying $10B+ deals to acquire external pipeline assets to fill the post-cliff revenue gap, a pattern shared with Merck. The IRA's 9-year small-molecule negotiation window has also been cited industry-wide as a factor pushing R&D funding away from small molecules toward biologics, a structural shift affecting Pfizer's future pipeline mix. Watch the outcome of Pfizer's legal challenges to IRA negotiation and the pace of bolt-on M&A as signals for whether the cliff is being managed or merely delayed.
What is PFE's intrinsic value and DCF price target?
A.L. Capital Advisory's model produces a blended fair-value range (25% pure DCF, 75% analyst consensus for well-covered names) of $33 (bear case) to $56 (bull case) for Pfizer Inc. (PFE). At $26.76, the margin of safety vs. blended base case is +37% (positive = discount to fair value; negative = premium). The bear-to-bull spread reflects genuine sensitivity to the two dominant DCF inputs: the terminal growth rate and the CAPM cost of equity (this model discounts EPS, an equity-level metric, so the cost of equity rather than a debt-weighted WACC is the applicable discount rate). Terminal value typically accounts for 60-80% of total intrinsic value in most equity DCF models, which is why a range is more analytically sound than a point estimate. The central analytical question is not what the DCF outputs as a single number but which growth trajectory the current market price already discounts. All DCF analysis follows CFA Institute standards and is conducted by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
Is PFE a buy or sell in 2026?
Pfizer Inc. (PFE) carries a Buy composite rating from A.L. Capital Advisory, consisting of a Strong Buy quantitative grade plus an analyst-conviction overlay. The quantitative grade is set by margin-of-safety band; the overlay is an additive analyst adjustment disclosed in the page's rating-calculation breakdown. Five-factor model scoring (Value, Quality, Momentum, Volatility, Size) and CVaR tail-risk measurement are shown separately on the page and are not inputs to this specific composite-rating formula. At $26.76, the margin of safety vs. blended base fair value is +37% (blended fair-value range: $33 bear – $56 bull). That places the current price in the Value zone of A.L. Capital Advisory's DCF framework, which sets the quantitative grade component before the analyst-conviction overlay is applied. Composite factor score: 3.0/5. Strongest factor: Volatility (5.0/5). Weakest factor: Quality (1.0/5). Trailing P/E: 34.3x. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Rating Methodology (this page) →
What is the average analyst target price for PFE?
Wall Street consensus target for PFE: $28.63 (+7.0% upside from the current price of $26.76). The analyst target range spans $25.00 (most bearish) to $35.46 (most bullish). Consensus recommendation: Buy. Note that analyst price targets typically reflect a 12-month forward horizon and are derived from a blend of DCF, comparable-company, and sum-of-the-parts analysis. A.L. Capital Advisory's Buy composite rating is calculated from the blended margin-of-safety grade, applicable automatic fundamental penalties, and a disclosed qualitative analyst-conviction overlay — not from five-factor scores or CVaR, which are supporting diagnostics shown elsewhere on this page. The displayed blended fair value combines the standalone DCF output with Street consensus for well-covered names (see the DCF Assumptions box for the exact blend weight), so it does not track Street consensus mechanically, but it is not fully independent of it either. When the composite rating and the Street consensus recommendation diverge, the divergence itself is informative: it can reflect differences in time horizon, valuation methodology, or the degree to which the current price already discounts the consensus case. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Data & Sources (this page) →
How does PFE score on Value, Quality, Momentum, Volatility, and Size?
PFE five-factor scores (A.L. Capital Advisory, 1–5 scale): Value 2.0/5 (below average) — measures the trailing P/E multiple versus the sector median (not the DCF or blended fair-value range, which are separate metrics on this page); Quality 1.0/5 (weak) — captures profitability metrics including return on equity (ROE: 5.0%) and net margin (6.8%) — sustained above-peer ROE and margins are the model's proxy for economic moat and pricing power; Momentum 3.0/5 (neutral) — reflects recent price trajectory and earnings surprise consistency; Volatility 5.0/5 (strong) — inverse measure derived from beta, where lower historical volatility earns a higher score; Size 4.0/5 (above average) — market capitalisation rank (mega-cap $1T+ scores 5/5). Composite: 3.0/5. Factor scores above 4.0 signal a tailwind in that dimension; below 2.0 signals a material headwind. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory.
What is PFE's tail risk and CVaR?
The 95th-percentile Conditional Value at Risk (CVaR) for PFE on a one-month horizon is -8.7%. CVaR represents the expected average loss in the worst 5% of monthly outcomes — a more conservative tail risk measure than standard VaR, which only marks the loss threshold. Beta of 0.28 indicates below-market systematic sensitivity — beta measures historical sensitivity to market moves, not total volatility. For reference, a diversified S&P 500 ETF carries a one-month CVaR of roughly -8% to -12% in normal market conditions; individual equity CVaR is higher due to idiosyncratic risk. At the portfolio level, what matters is the marginal CVaR contribution of each holding — not its standalone figure. The A.L. Capital Advisory Portfolio Health Check quantifies each position's marginal tail-risk contribution across your entire holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: CVaR & Tail-Risk Methodology →
What would trigger a rating upgrade or downgrade for PFE?
Upgrade trigger: Upgrade to Strong Buy on evidence of accelerating earnings surprise magnitude combined with improvement in the Value factor score — specifically if the current 34.3x P/E is supported by an upward revision to DCF terminal growth assumptions. Downgrade trigger: An earnings miss at current valuations (34.3x trailing P/E) where there is limited earnings cushion to absorb negative surprises; or a sustained reversal in the Quality and Momentum factor scores for two or more consecutive quarters. These triggers are reassessed each time the underlying fundamentals, price, or earnings data refresh — the current Buy rating is not held on a fixed review calendar. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Rating Methodology (this page) →
Does PFE consistently beat earnings estimates?
PFE has beaten consensus EPS estimates in 4 of the 4 most recently reported quarters (100%) — indicating consistent delivery across the latest 4 reported quarters. The most recent reported quarter beat consensus by 12.9%. Sustained above-consensus delivery supports both the Momentum and Quality factor scores and provides a tailwind to the current rating. Across the 4 most recently reported quarters with valid consensus data, a beat rate above 70% signals consistent execution in this model, while a rate below 50% typically corresponds to a Momentum factor score of 3.0/5 or below. Earnings surprise magnitude and direction are incorporated into the Momentum and Quality dimensions of the five-factor scoring model. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Earnings History (this page) →
How does PFE contribute to portfolio risk and diversification?
PFE carries a beta of 0.28 (low-volatility / defensive relative to the broad equity market). A beta above 1.0 means the position amplifies market moves in both directions at a typical portfolio weight. Strongest peer co-movement: BMY (0.58), MRK (0.52), AZN (0.48). Holding PFE alongside these names in the same portfolio increases concentration risk. True portfolio risk is a function of the full covariance structure — a single stock's beta does not reveal its marginal contribution to portfolio tail loss. The A.L. Capital Advisory Portfolio Health Check quantifies concentration risk (Herfindahl-Hirschman Index), pairwise correlations, and marginal CVaR contribution across all your holdings. If a single position such as this one makes up an outsized share of your net worth — employer stock, RSUs, or concentrated equity compensation — a Strategic Session builds the sequencing plan and the written allocation that follows from it. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Ledoit-Wolf Covariance Framework →
What quantitative methodology does A.L. Capital Advisory use to analyse PFE?
A.L. Capital Advisory analyses Pfizer Inc. (PFE) using a four-part quantitative research framework grounded in CFA Institute standards (not all four parts feed the composite rating formula directly — see below). (1) DCF Valuation: a two-stage earnings-based DCF that projects EPS (not free cash flow) under bear and bull assumptions, discounts at the CAPM cost of equity (the applicable rate for an equity-level metric like EPS, not a debt-weighted WACC) to produce an intrinsic value range with margin-of-safety calculation. (2) Five-Factor Scoring: each equity is scored 1–5 on Value, Quality, Momentum, Volatility, and Size. (3) CVaR Tail Risk: 95th-percentile Conditional Value at Risk from historical simulation of daily returns on a one-month horizon. (4) Earnings Surprise Analysis: quarterly beat rate and magnitude, shown for context alongside the factor scores. The current Buy composite rating for PFE is calculated separately from this broader framework: it consists of a Strong Buy quantitative grade, any automatic fundamental penalty, and a disclosed qualitative analyst-conviction overlay — see this page's Rating Methodology section for the exact formula. Five-factor scoring, CVaR and earnings surprise analysis below are supporting research diagnostics shown separately on this page; they are not direct numerical inputs into this specific composite-rating calculation. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework → · CVaR & Tail-Risk Methodology →
Stress-Test This View Live
Run PFE in Asset Lens
Live DCF valuation, Monte Carlo simulation, options flow intelligence, and full factor decomposition — updated in real time. Free, no account required.
Retrieved 2026-08-08T10:24:15+00:00 (UTC); see per-quarter analyst counts in Earnings Forecast; individual target ages/dates are not disclosed by the data provider
Most recent exchange settlement date on file with the data provider (exact settlement date not exposed by the provider's API; retrieved 2026-08-08T10:24:15+00:00 UTC)
[6] DCF valuation, five-factor model & composite rating
Calculated 2026-08-08T10:24:15+00:00 (UTC); see Rating Methodology above for the exact formula
Hand-authored thesis commentary (bull/bear case, catalysts, AI-Era Durability Score narrative) is cross-checked against the company's own investor-relations disclosures at time of writing; figures presented as A.L. Capital Advisory estimates are proprietary forecasts, not company guidance, unless explicitly attributed to the issuer.
Market-session status above is derived from the page's UTC generation time using standard NYSE hours (9:30am–4:00pm ET regular session); it does not account for US market holidays and may be inaccurate on those dates.
Download this page's underlying data: JSON → · CSV →
Legal Disclaimer & Important Notices
This analysis is produced using a systematic quantitative framework applied to market data and does not constitute investment advice. Prose commentary is AI-assisted and generated from structured quantitative inputs. All data and metrics are as of 2026-08-08 and are point-in-time estimates subject to revision without notice. CVaR figures are based on historical simulation and do not guarantee future outcomes. DCF ranges and upgrade/downgrade triggers are forward-looking statements based on current assumptions and may not materialise. Past performance does not guarantee future results. This analysis does not account for individual circumstances, tax position, or investment objectives — consult a qualified financial advisor before making investment decisions. This content is intended for informational purposes only and does not constitute regulated investment advice under MiFID II or FCA guidelines. This content is not intended for US persons or residents of jurisdictions where its distribution would be contrary to local law or regulation. This service is not directed at residents of Finland, Sweden, Norway, Denmark, Iceland, or Poland. The author may hold long or short positions in securities mentioned in this analysis. Nothing on this page represents a solicitation to buy or sell any security. A.L. Capital Advisory is an independent private advisory practice and is not affiliated with Pfizer Inc.
CFA Portfolio Advisory — PFE
Discuss this analysis, position sizing, or your full portfolio mandate with Anton Ladnyi, CFA.
